Remarks

• In the GDG's assessment, only a minority of low-risk patients will choose to consider using nirmatrelvir-ritonavir.
• Trials on antivirals included patients with some risk factors for hospital admission, resulting in a baseline risk of 3% that the GDG applied to generate the recommendation. The risk of hospitalization is likely to be lower in the general population.
• Clinicians should not consider nirmatrelvir-ritonavir in pregnant women, children, or those with possible dangerous drug interactions (note: many drugs interact with nirmatrelvir-ritonavir).

Practical Info Route, dosage and duration: Additional considerations are available in a summary of practical issues. In any patient being considered for nirmatrelvir-ritonavir use, clinicians need to give serious consideration to drug interactions. The Liverpool COVID-19 drug interaction checker may be useful in this regard (28).